

## Six Trigalactosylceramides from the Leech (*Hirudo nipponica*)

Naoki NODA,\*<sup>a</sup> Ryuichiro TANAKA,<sup>a</sup> Kazumoto MIYAHARA,<sup>a</sup> and Takayuki SUKAMOTO<sup>b</sup>

*Faculty of Pharmaceutical Sciences, Setsunan University,<sup>a</sup> 45-1, Nagaotoge-cho, Hirakata, Osaka 573-01, Japan and New Drug Research Laboratories, Kanebo, Ltd.,<sup>b</sup> 5-90, Tomobuchi-cho 1-chome, Miyakojima-ku, Osaka 534, Japan.*

Received November 10, 1995; accepted January 17, 1996

Six neutral glycosphingolipids were isolated in the pure state from the leech, *Hirudo nipponica* (Annelida). In contrast to the zwitterionic monogalactosylceramides carrying a choline phosphate group so far obtained, all compounds are non-zwitterionic glycosphingolipids, trigalactosylceramides. Five compounds possess a Galz1-6Galz1-6Galβ1-Cer core, and one is unique in having a Galz1-6Galβ1-6Galβ1-Cer structure. Their full structures have been determined on the bases of chemical and spectral evidence.

**Key words** glycosphingolipid; trigalactosylceramide; leech; *Hirudo nipponica*; Annelida

Since the finding and isolation of remarkably large amounts of alkylglycerophosphocholines from the earth worm (*Pheretima asiatica*),<sup>1)</sup> we have been interested in the constituents, especially the lipid composition, in members of the phylum Annelida. Up to now, about thirty homogenous zwitterionic monogalactosylceramides (ZGSLs)<sup>2)</sup> carrying a choline phosphate group, as well as various alkyl ether-type glycerophosphocholines,<sup>3)</sup> have been isolated from various annelids. We have continued our preceding study<sup>4)</sup> on the lipid composition in members of the phylum, and have isolated six glycosphingolipids (GSLs) in pure form from the leech, *Hirudo nipponica*. Analyses of their spectral data and of the components of the parent GSLs demonstrated that all of them are neutral glycosphingolipids, trigalactosylceramides of Galz1-6Galz1-6Galβ1-Cer or Galz1-6Galβ1-6Galβ1-Cer type. This paper deals with the isolation and structure elucidation of these compounds.

### Results and Discussion

The total lipid fraction obtained from the CHCl<sub>3</sub>-MeOH extract of the whole dried bodies of the materials was subjected to silica gel and Cosmosil 75C<sub>18</sub>-OPN column chromatographies with various solvents to yield a crude glycolipid fraction (fr. 9).<sup>4)</sup> It contains at least 17 components, as revealed by HPLC. We applied repeated-recycling preparative HPLC with a reverse-phase column, and succeeded in isolating six compounds **1**–**6** in a pure state.

The negative ion FAB-MS of **1** exhibited a pseudo-molecular ion and fragment ion peaks arising from cleavage of glycosidic linkages at *m/z* 1186 [*M*–H]<sup>–</sup>, 1024 (1186–hexosyl unit), 862 (1024–hexosyl unit) and 700 (862–hexosyl unit). The <sup>1</sup>H-NMR spectrum of **1** showed three anomeric proton signals at δ 4.22 (*J*=7.3 Hz), 4.85 (*J*=4.3 Hz) and 4.99 (*J*=4.3 Hz) and six olefinic hydrogens, in addition to signals ascribable to three methylenes next to a double bond (6H, δ 2.03–2.06) and to a methylene located between two double bonds, but it gave no signals due to a phosphocholine unit as in the ZGSLs so far obtained.<sup>2,4)</sup> In the <sup>13</sup>C-NMR spectrum, the chemical shifts of signals due to a ceramide group (Cer) closely corresponded to those found in the ZGSLs with a triunsaturated long-chain base (LCB), suggesting that **1** is a ceramide trisaccharide possessing a 1,4-pentadiene-1,5-

diyl (–CH=CH–CH<sub>2</sub>–CH=CH–) group.<sup>4)</sup>

Methanolysis of **1** with 7.5% HCl–MeOH liberated a fatty acid methyl ester and a sugar unit. The former was analyzed by gas chromatography (GC) and electron impact mass spectrometry (EI-MS), which revealed methyl *n*-tetracosanoate. The latter was converted into a trimethylsilyl ether, which in GC gave peaks identical with those of authentic trimethylsilyl ester of methyl galactoside. By the method of Hara *et al.*,<sup>5)</sup> the galactose unit was proved to have D form. From these findings, in conjunction with the molecular weight (M.W. 1187), compound **1** was considered to be a trigalactosylceramide with the same C<sub>22:3</sub> docosasphingatrienine as that of the ZGSLs reported previously.<sup>4)</sup>

According to the Vincenti method,<sup>6)</sup> compound **1** was converted into the dimethyl disulfide derivative (**1a**). Its EI-MS exhibited the diagnostically important fragment ion peak at *m/z* 201, which was regarded as being due to a fragment ion produced by cleavage between the C-11 and C-12 sulfided carbons. The two-dimensional shift correlation (<sup>1</sup>H–<sup>1</sup>H COSY) spectrum gave a series of correlation peaks from H-3 to H<sub>2</sub>-7, and also showed a cross peak between H<sub>2</sub>-7 and olefinic hydrogen. These findings showed that the 1,4-pentadiene-1,5-diyl group is located at C-8.

The two-dimensional nuclear Overhauser effect (NOE-SY) spectrum of **1** gave a correlation peak between H-4 and H<sub>2</sub>-6, and therefore the geometry of the double bond at C-4 was concluded to be *trans*. On the other hand, because of overlapping of the signals, that of the double bonds at C-8 and C-11 was determined from the chemical shifts of the allylic carbon signals. In the <sup>13</sup>C-NMR spectrum, both allylic carbons (C-7 and C-13) were observed at δ 27.8, while the bis-allylic one (the C-10 carbon between the two double bonds, C-8 and C-11) appeared at δ 26.1. On the basis of their chemical shifts,<sup>7,8)</sup> the geometry of both two double bonds (C-8 and C-11) was assigned as *cis*.

Hydrogenation over palladium carbon of **1** followed by methanolysis gave a saturated LCB, which was acetylated to give an LCB triacetate (**1b**), which was identified as D-erythro-docosasphinganine triacetate by comparison of the optical rotation and spectral data with those of an authentic sample.<sup>4)</sup> From the information obtained above, it was clear that the sphingosine unit of **1** was

\* To whom correspondence should be addressed.




Fig. 1. HMBC Correlations of **1**

*D-erythro*-(4*E*,8*Z*,11*Z*)-docosasphingatrienine.

The position and mode of the glycosidic linkages were determined by two-dimensional heteronuclear multiple bond connectivity spectroscopy (HMBC). In the HMBC spectrum, significant correlation peaks, H-1 of the inner galactose (Gal)/C-1 of Cer, H-1 of the middle galactose (Gal')/C-6 of Gal and H-1 of the outer galactose (Gal'')/C-6 of Gal' were observed (Fig. 1). The configuration at the C-1 position of each of Gal, Gal' and Gal'' was concluded to be  $\beta$ ,  $\alpha$  and  $\alpha$ , respectively, judging from the coupling constants and chemical shifts of the corresponding C-1 carbon<sup>9)</sup> found in the <sup>1</sup>H- and <sup>13</sup>C-NMR spectra (Table).

On the basis of all the results described above, the structure of **1** was determined to be *N*-tetracosanoyl-1-*O*-[ $\alpha$ -D-galactopyranosyl-(1 $\rightarrow$ 6)- $\alpha$ -D-galactopyranosyl-(1 $\rightarrow$ 6)- $\beta$ -D-galactopyranosyl]-(4*E*,8*Z*,11*Z*)-docosasphingatrienine.

The <sup>1</sup>H- and <sup>13</sup>C-NMR spectra of compounds **2**–**5** were almost indistinguishable from each other, except for signals due to methyl groups, and signals assignable to the sugar moieties were closely correlated with those of **1**, suggesting that they are analogs of **1**. By analyses of the NMR spectral data and of the degradation products of each compound in the same manner as described for **1**, they were found to have the same oligosaccharide moiety, Gal $\alpha$ 1-6Gal $\alpha$ 1-6Gal $\beta$ 1-Cer, as that of **1**. The ceramide part of each of **2**–**5** was identified as *N*-hexadecanoyl-(4*E*)-octadeca- and *N*-hexadecanoyl-(4*E*)-nonadecasphing-

enines, and *N*-docosadecanoyl-(4*E*)-17-methyloctadecanoyl- and *N*-tetracosanoyl-(4*E*)-17-methyloctadecasphing-enines, respectively, by comparison of the physical and spectral data with the corresponding values of authentic samples,<sup>2,4)</sup> and their structures were thus characterized as represented in Fig. 2.

The <sup>1</sup>H-NMR spectrum of **6**, in contrast to those of **1**–**5**, differed markedly in the chemical shifts of signals arising from the sugar moiety, including those of the three anomeric protons, 4.24 ( $J=7.3$  Hz), 4.25 ( $J=7.3$  Hz) and 4.90 ( $J=4.3$  Hz). Analyses of the components produced by the chemical degradation of **6** revealed that it contains *N*-hexadecanoyl-(4*E*)-octadecasphingene and that its oligosaccharide consists solely of galactose. These findings demonstrated that **6** is another trigalactosylceramide, differing from **1**–**5** in the oligosaccharide linkage. The HMBC spectrum of **6** gave notable correlation peaks, H-1 of Gal/C-1 of Cer, H-1 of Gal'/C-6 of Gal and H-1 of Gal''/C-6 of Gal', confirming the positions of the sugar linkage. The configurations of the C-1 positions of Gal, Gal' and Gal'' were concluded to be  $\beta$ ,  $\beta$  and  $\alpha$ , respectively, based on the coupling constants of the anomeric proton signals (Table 1). Consequently, **6** was defined as *N*-hexadecanoyl-1-*O*-[ $\alpha$ -D-galactopyranosyl-(1 $\rightarrow$ 6)- $\beta$ -D-galactopyranosyl-(1 $\rightarrow$ 6)- $\beta$ -D-galactopyranosyl]-(4*E*)-octadecasphingene.

Thus, six trigalactosylceramides were isolated in pure form. Among them, five compounds (**1**–**5**) possess a Gal $\alpha$ 1-6Gal $\alpha$ 1-6Gal $\beta$ 1-Cer core,<sup>10)</sup> and the last (**6**) is




Fig. 2

unique in having a Gal $\alpha$ 1-6Gal $\beta$ 1-6Gal $\beta$ 1-Cer structure. In view of the similarity of the sphingosine units of compounds 1–6 to those of phosphocholine-linked mono-galactosylceramides,<sup>4)</sup> these neutral GSLs are likely to be precursors of amphoteric galactocerebrosides.

#### Experimental

The NMR spectra were recorded on a JEOL JMN GSX 400 instrument at 400 MHz ( $^1\text{H}$ ) and 100 MHz ( $^{13}\text{C}$ ) at a probe temperature of 35 °C using tetramethylsilane as an internal reference. MS were acquired on a JEOL JMS DX-300 spectrometer (EI-MS: ionization voltage, 30 eV; accelerating voltage, 3–10 kV. Positive ion FAB-MS: accelerating voltage, 3 kV; matrix, glycerol; collision gas, Xe). Optical rotations were measured (24–26 °C) with a JASCO DIP-140 polarimeter. TLC was carried out on silica gel HPTLC with Al sheets (Merck Art. 5556). Spots were visualized with 5%  $\text{H}_2\text{SO}_4$  in MeOH (by heating). Column chromatography was carried out on Merck Silica gel (230–400 mesh, Art. 9385), and Cosmosil 75C<sub>18</sub>-OPN (Nacalai Tesque). Preparative HPLC was conducted over an L-column octadecyl silica (10  $\times$  250 mm, Chemicals Inspection & Testing Ins.) on a JASCO PU-980 equipped with a model 504R unit (GL Sciences). Recycling HPLC was carried out on a JASCO PU-980 equipped with a JASCO preparative recycle valve. The analytical GC was carried out with a Hitachi G-3000 equipped with a 30:1 splitter and a flame ionization detector.

**Isolation of GSLs 1–6** The  $\text{CHCl}_3$ -MeOH extractives (72.2 g) of the crushed powder (1 kg) of the leech, *Hirudo nipponica* (sold as a crude drug "Suitetsu," purchased from Tochimoto Tenkaido, 1993), were treated with  $\text{CHCl}_3$ -MeOH- $\text{H}_2\text{O}$  (1:1:1, 600 ml), and the lower layer was collected and concentrated to give a total lipid fraction (55.6 g). It was placed on a silica gel column and eluted successively with  $\text{CHCl}_3$ -MeOH (8:2  $\rightarrow$  7:3)  $\rightarrow$   $\text{CHCl}_3$ -MeOH- $\text{H}_2\text{O}$  (7:3:0.5  $\rightarrow$  6:4:1  $\rightarrow$  5:5:1) to give six fractions, fr. 1 (38.3 g), fr. 2 (3.3 g), fr. 3 (1.9 g), fr. 4 (4.6 g), fr. 5 (1.8 g) and fr. 6 (4.5 g). Fraction 4 was further separated by silica gel column chromatography with  $\text{CHCl}_3$ -MeOH (7:3) to give fr. 5 (2.7 g), fr. 6 (1.1 g) and fr. 7 (0.7 g). Fraction 6 was subjected to chromatography on a 75C<sub>18</sub>-OPN column using MeOH  $\rightarrow$   $\text{CHCl}_3$ -MeOH (1:1) as the eluent to yield three fractions, fr. 8 (270 mg), fr. 9 (464 mg) and fr. 10 (62 mg). Fraction 9 was separated by HPLC (mobile phase:  $\text{CHCl}_3$ -MeOH, 1.5:10) to give seventeen GSL fractions, 9-1 (14.6 mg), 9-2 (19.8 mg), 9-3 (15.4 mg), 9-4 (19.1 mg), 9-5 (11.4 mg), 9-6 (7.7 mg), 9-7 (42.0 mg), 9-8 (10.0 mg), 9-9 (25.0 mg), 9-10 (8.0 mg), 9-11 (15.0 mg), 9-12 (20.0 mg), 9-13 (35.0 mg), 9-14 (8.0 mg), 9-15 (10.0 mg), 9-16 (13.0 mg) and 9-17 (8.0 mg). Among them, selected fractions (9-2, 9-3, 9-9, 9-12 and 9-13) were purified by HPLC in a recycling mode by use of  $\text{CHCl}_3$ -MeOH- $\text{H}_2\text{O}$  (5:20:1). The solvent of each fraction was evaporated under a nitrogen stream to yield compounds 1 and 5 (11.0 and 10.0 mg, 8 cycles from fr. 9-13), 2 and 6 (3.8 and 4.4 mg, 17 cycles from fr. 9-2), 3 (5.0 mg, 30 cycles) and 4 (11.3 mg, 19 cycles from fr. 9-9). 1: mp 135–146 °C,  $[\alpha]_D^{25} + 46.7^\circ$  ( $c = 1.1$ ,  $\text{CHCl}_3$ -MeOH, 1:1). Negative ion FAB-MS  $m/z$  (rel. int.): 1186  $[\text{M}-\text{H}]^-$  (100), 1024 (32),

Table 1.  $^{13}\text{C}$ - and  $^1\text{H}$ -NMR Spectral Data for Glycosphingolipids ( $\text{CDCl}_3\text{-CD}_3\text{OD}$ )

No.	1		2		3	
	$^{13}\text{C}$	$^1\text{H}$	$^{13}\text{C}$	$^1\text{H}$	$^{13}\text{C}$	$^1\text{H}$
Cer 1	69.4	3.50 (dd, 7.0, 10.0) 4.18 (dd, 4.0, 10.0)	69.6	3.51 (dd, 7.0, 10.0) 4.19 (dd, 4.0, 10.0)	69.6	3.49 (dd, 7.0, 10.0) 4.18 (dd, 4.0, 10.0)
Cer 2	53.6	3.97 (m)	53.9	3.96 (m)	53.8	3.96 (m)
Cer 3	72.0	4.12 (t, 7.0)	71.6	4.11 (t, 7.0)	71.5	4.10 (t, 7.0)
Cer 4	130.4	5.44 (dd, 7.0, 15.0)	130.6	5.45 (dd, 7.0, 15.0)	130.5	5.44 (dd, 7.0, 15.0)
Cer 5	134.7	5.70 (ddd, 7.0, 8.0, 15.0)	134.8	5.70 (ddd, 7.0, 8.0, 15.0)	134.8	5.69 (ddd, 7.0, 8.0, 15.0)
Cer 6	33.0	2.03	32.6	2.02	32.5	2.04
Cer 7	27.8	2.06	—	ca. 1.28	—	ca. 1.27
Cer 8	130.6	5.30—5.40	—	ca. 1.28	—	ca. 1.27
Cer 9	128.5	5.30—5.40	—	ca. 1.28	—	ca. 1.27
Cer 10	26.1	2.78 (2H, t, 7.0)	—	ca. 1.28	—	ca. 1.27
Cer 11	128.4	5.30—5.40	—	ca. 1.28	—	ca. 1.27
Cer 12	130.5	5.30—5.40	—	ca. 1.28	—	ca. 1.27
Cer 13	27.8	2.06	—	ca. 1.28	—	ca. 1.27
$-\text{CH}-(\text{CH}_3)_2$	—	—	—	—	—	—
CH <sub>3</sub>	14.2	0.88 (3H, t, 7.0)	14.3	0.89 (3H, t, 7.0)	14.3	0.88 (3H, t, 7.0)
FA 2''	175.1	2.17 (2H, t, 7.0)	175.3	2.17 (2H, t, 7.0)	175.2	2.14 (2H, t, 7.0)
CH <sub>3</sub>	14.2	0.88 (3H, t, 7.0)	14.3	0.89 (3H, t, 7.0)	14.3	0.88 (3H, t, 7.0)
Gal 1	104.5	4.22 (d, 7.3)	104.7	4.20 (d, 7.3)	104.7	4.18 (d, 7.3)
Gal 2	72.3	3.53	72.2	3.53	72.2	3.51
Gal 3	73.9	3.52	74.2	3.52	74.1	3.50
Gal 4	69.5	3.85 (dd, 1.0, 3.0)	69.7 <sup>a)</sup>	3.85 (dd, 1.0, 3.0)	69.7	3.84 (dd, 1.0, 3.0)
Gal 5	74.1	3.73	74.3	3.73	74.2	3.74
Gal 6	66.4	3.60 (dd, 4.5, 10.5) 4.02 (dd, 7.5, 10.5)	66.7	3.60 (dd, 4.5, 10.5) 4.02 (dd, 7.5, 10.5)	66.6	3.58 (dd, 4.5, 10.5) 4.01 (dd, 7.5, 10.5)
Gal' 1	98.4	4.85 (d, 4.3)	99.0	4.87 (d, 4.3)	98.9	4.86 (d, 4.3)
Gal' 2	70.9	3.80	71.0	3.80	70.9	3.78
Gal' 3	69.5	3.80	69.8 <sup>a)</sup>	3.80	69.7	3.78
Gal' 4	70.3	3.90	70.6	3.91	69.8	3.90
Gal' 5	69.2	4.18 (m)	69.4	4.18 (m)	68.3	4.16 (m)
Gal' 6	67.0	3.68 (dd, 4.5, 10.5) 3.90	67.3	3.67 (dd, 4.5, 10.5) 3.91	67.2	3.66 (dd, 4.5, 10.5) 3.90
Gal'' 1	98.4	4.99 (d, 4.3)	98.8	4.98 (d, 4.3)	98.7	4.98 (d, 4.3)
Gal'' 2	70.6	3.80	70.9	3.80	70.8	3.80
Gal'' 3	69.6	3.78	69.9	3.78	69.7	3.78
Gal'' 4	70.4	3.94 (dd, 1.0, 3.0)	70.9	3.94 (dd, 1.0, 3.0)	70.6	3.94 (dd, 1.0, 3.0)
Gal'' 5	71.3	3.90	71.0	3.91	71.0	3.90
Gal'' 6	62.3	3.73	62.4	3.73	62.4	3.74

862 (32), 700 (36). Positive ion FAB-MS  $m/z$ : 1211  $[\text{M} + \text{Na} + \text{H}]^+$ . 2: mp 130—138 °C,  $[\alpha]_{\text{D}} + 51.6^\circ$  ( $c=0.4$ ,  $\text{CHCl}_3\text{-MeOH}$ , 1:1). Positive ion FAB-MS  $m/z$ : 1047  $[\text{M} + \text{Na} + \text{H}]^+$ . 3: mp 130—140 °C,  $[\alpha]_{\text{D}} + 41.7^\circ$  ( $c=0.5$ ,  $\text{CHCl}_3\text{-MeOH}$ , 1:1). Positive ion FAB-MS  $m/z$ : 1061  $[\text{M} + \text{Na} + \text{H}]^+$ . 4: mp 133—146 °C,  $[\alpha]_{\text{D}} + 55.4^\circ$  ( $c=1.1$ ,  $\text{CHCl}_3\text{-MeOH}$ , 1:1). Positive ion FAB-MS  $m/z$ : 1145  $[\text{M} + \text{Na} + \text{H}]^+$ . 5: mp 137—145 °C,  $[\alpha]_{\text{D}} + 52.8^\circ$  ( $c=1.0$ ,  $\text{CHCl}_3\text{-MeOH}$ , 1:1). Positive ion FAB-MS  $m/z$ : 1173  $[\text{M} + \text{Na} + \text{H}]^+$ . 6: mp 132—138 °C,  $[\alpha]_{\text{D}} + 8.3^\circ$  ( $c=0.8$ ,  $\text{CHCl}_3\text{-MeOH}$ , 1:1). Positive ion FAB-MS  $m/z$ : 1047  $[\text{M} + \text{Na} + \text{H}]^+$ .  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR spectral data of 1—6 ( $\text{CDCl}_3\text{-CD}_3\text{OD}$ , 1:1)  $\delta$ : see Table.

**Analysis of the Fatty Acids** Each (ca. 2 mg) of 1—6 was treated with 5% methanolic HCl at 90 °C for 1 h. The fatty acid methyl ester produced was extracted with *n*-hexane, and analyzed by GC (fused silica capillary column Bonded MPS-50, Quadrex, 0.25 mm  $\times$  50 m; column temperature, 230 °C (hold, 12 min)  $\rightarrow$  240 °C at 1 °C/min; carrier gas, He at 33.4 ml/min);  $t_{\text{R}}$  (min): 6.54 (methyl *n*-hexadecanoate from 2, 3 and 6), 21.02 (methyl *n*-docosanoate from 4), 31.75 (methyl *n*-tetracosanoate from 1 and 5). Each fatty acid methyl ester was identified by EI-MS comparison with an authentic sample of the corresponding methyl ester.

**Analysis of the Sugar Unit** The MeOH layer obtained above was evaporated to dryness to give a methyl glycoside fraction. A part of the fraction was treated with *N*-trimethylsilylimidazole and the product was examined by GC (fused silica capillary column Bonded MPS-50, Quadrex, 0.25 mm  $\times$  50 m; column temperature, 180 °C; carrier gas, He at 33.4 ml/min).  $t_{\text{R}}$  (min): 11.0, 12.2, 12.6, 13.7. The peaks were identical with those of authentic methyl galactose derivatives.

The remaining methyl glycoside fraction was heated with 1 ml of 2N

HCl at 90 °C for 1 h. The reaction mixture was neutralized with  $\text{Ag}_2\text{CO}_3$ . The precipitate was removed by centrifugation and the supernatant was shaken with  $\text{CHCl}_3$  (1 ml). The  $\text{CHCl}_3$  layer was separated and evaporated to dryness under a nitrogen stream. The residue was applied to a Sephadex LH-20 column and eluted with MeOH to give a sugar fraction. This was analyzed by GC according to the method described in the preceding paper,<sup>4)</sup> and identified as the D-galactose derivative ( $t_{\text{R}}$ , 19.45 and 19.52 min).

**Preparation of the Dimethyl Disulfide Derivative** Carbon disulfide (0.2 ml) and iodine (1 mg) were added to 1 (2 mg) in dimethyl disulfide (0.2 ml), and the mixture was kept at 60 °C for 40 h. The reaction was quenched with 5% aqueous solution of sodium thiosulfate, then the mixture was shaken with  $\text{CHCl}_3\text{-MeOH}$  (1:1, 3 ml). The lower layer was separated and concentrated under a nitrogen stream. The product (1a) was subjected to analysis by EI-MS. 1a: EI-MS  $m/z$ : 201  $[\text{C}_{12}\text{H}_{25}\text{S}]$ .

**Hydrogenation of the LCB Part** Compound 1b (10 mg) was hydrogenated over 10% palladium carbon (100 mg) in  $\text{CHCl}_3\text{-MeOH}$  (1:4, 50 ml). The catalyst was filtered off and the filtrate was evaporated to dryness to give a product. This was methanolized with 7.5% methanolic HCl at 90 °C for 2 h. The fatty acid formed was extracted with *n*-hexane and the methanolic layer was neutralized by adding a small excess of  $\text{Ag}_2\text{CO}_3$ . After centrifugation, the supernatant was evaporated to dryness to give a residue. The residue was chromatographed on a Sephadex LH-20 column with MeOH, yielding a product. This was acetylated with acetic anhydride-pyridine (1:1, 1 ml) at room temperature for 1 d to give an LCB triacetate (1b, 3 mg). 1b:  $[\alpha]_{\text{D}} + 8.0^\circ$  ( $c=0.1$ ,  $\text{CHCl}_3$ ). Positive ion FAB-MS  $m/z$ : 484  $[\text{M} + \text{H}]^+$ . The  $^1\text{H}$ -NMR was in accord with that of D-erythro-docosasphinganine. Each of

Table 1. (continued)

No.	4		5		6	
	<sup>13</sup> C	<sup>1</sup> H	<sup>13</sup> C	<sup>1</sup> H	<sup>13</sup> C	<sup>1</sup> H
Cer 1	69.6	3.50 (dd, 7.0, 10.0) 4.19 (dd, 4.0, 10.0)	70.1	3.50 (dd, 7.0, 10.0) 4.19 (dd, 4.0, 10.0)	69.4	3.62 (dd, 7.0, 10.0) 4.19 (dd, 4.0, 10.0)
Cer 2	54.0	3.98 (m)	54.3	3.98 (m)	54.1	3.97 (m)
Cer 3	71.6	4.13 (t, 7.0)	72.6	4.13 (t, 7.0)	72.5	4.12 (t, 7.0)
Cer 4	130.7	5.45 (dd, 7.0, 15.0)	130.9	5.44 (dd, 7.0, 15.0)	130.2	5.45 (dd, 7.0, 15.0)
Cer 5	134.8	5.71 (ddd, 7.0, 8.0, 15.0)	135.4	5.70 (ddd, 7.0, 8.0, 15.0)	134.7	5.70 (ddd, 7.0, 8.0, 15.0)
Cer 6	32.6	2.02	33.1	2.03	32.5	2.03
Cer 7	—	ca. 1.28	—	ca. 1.27	—	ca. 1.28
Cer 8	—	ca. 1.28	—	ca. 1.27	—	ca. 1.28
Cer 9	—	ca. 1.28	—	ca. 1.27	—	ca. 1.28
Cer 10	—	ca. 1.28	—	ca. 1.27	—	ca. 1.28
Cer 11	—	ca. 1.28	—	ca. 1.27	—	ca. 1.28
Cer 12	—	ca. 1.28	—	ca. 1.27	—	ca. 1.28
Cer 13	—	ca. 1.28	—	ca. 1.27	—	ca. 1.28
—CH—(CH <sub>3</sub> ) <sub>2</sub>	27.8	1.55 <sup>b)</sup>	28.5	1.54 <sup>b)</sup>	—	—
CH <sub>3</sub>	22.9	0.89 (6H, d, 7.0)	23.8	0.88 (6H, d, 7.0)	14.2	0.89 (3H, t, 7.0)
FA 2''	175.3	2.16 (2H, t, 7.0)	175.7	2.17 (2H, t, 7.0)	175.2	2.17 (2H, t, 7.0)
CH <sub>3</sub>	14.3	0.89 (3H, t, 7.0)	14.9	0.88 (3H, t, 7.0)	14.3	0.89 (3H, t, 7.0)
Gal 1	104.8	4.22 (d, 7.3)	105.1	4.21 (d, 7.3)	104.6	4.24 (d, 7.3)
Gal 2	72.3	3.53	72.7	3.53	72.0	3.53
Gal 3	74.2	3.52	74.6	3.52	74.2	3.53
Gal 4	69.8	3.85 (dd, 1.0, 3.0)	70.1 <sup>a)</sup>	3.85 (dd, 1.0, 3.0)	69.3	3.88 (dd, 1.0, 3.0)
Gal 5	74.3	3.73	74.7	3.73	74.1 <sup>a)</sup>	3.75
Gal 6	66.8	3.60 (dd, 4.5, 10.5) 4.00 (dd, 7.5, 10.5)	67.1	3.60 (dd, 4.5, 10.5) 4.00 (dd, 7.5, 10.5)	68.5	3.88 3.99 (dd, 7.5, 10.5)
Gal' 1	99.1	4.88 (d, 4.3)	99.3	4.88 (d, 4.3)	104.2	4.25 (d, 7.3)
Gal' 2	70.9	3.80	71.5	3.80	72.0	3.54
Gal' 3	69.8	3.80	70.2 <sup>a)</sup>	3.80	74.2	3.54
Gal' 4	70.6	3.92	70.9	3.90	69.3	3.90
Gal' 5	69.5	4.18 (m)	69.8	4.18 (m)	74.6 <sup>a)</sup>	3.75
Gal' 6	67.4	3.69 (dd, 4.5, 10.5) 3.92	67.8	3.68 (dd, 4.5, 10.5) 3.90	67.5	3.65 (dd, 4.5, 10.5) 3.93
Gal'' 1	98.9	4.99 (d, 4.3)	99.1	4.99 (d, 4.3)	99.8	4.90 (d, 4.3)
Gal'' 2	70.9	3.80	71.3	3.80	69.7	3.80
Gal'' 3	69.8	3.78	70.2	3.78	70.9	3.78
Gal'' 4	70.6	3.94 (dd, 1.0, 3.0)	71.1	3.95 (dd, 1.0, 3.0)	70.4	3.94 (dd, 1.0, 3.0)
Gal'' 5	71.1	3.92	71.9	3.90	71.6	3.91
Gal'' 6	62.4	3.73	63.0	3.73 3.80	62.2	3.74 3.80

Coupling constants (*J*) in Hz are given in parentheses. Cer, ceramide unit; FA, fatty acid unit; Gal, galactose unit. <sup>a)</sup> The assignments may be interchanged. <sup>b)</sup> Signals appeared as a septet (*J*=7.0 Hz) because of overlapping.

**2–6** was treated in the same manner as described for **1**, and the long-chain bases formed were identified as *D-erythro*-octadeca- (from **2** and **6**), *D-erythro*-nonadeca- (from **3**), and *D-erythro*-17-methyloctadecaphingianines (from **4** and **5**).

**Acknowledgments** The authors wish to thank Dr. Masatoshi Nishi and Mr. Shoji Inoue of this university for measurements of the NMR spectra and MS.

#### References and Notes

- Noda N., Tsunefuka S., Tanaka R., Miyahara K., *Chem. Pharm. Bull.*, **40**, 1349 (1992); *idem, ibid.*, **40**, 2756 (1992).
- Noda N., Tanaka R., Miyahara K., Kawasaki T., *Tetrahedron Lett.*, **33**, 7527 (1992); *idem, Biochim. Biophys. Acta*, **1169**, 30 (1993); *idem, Chem. Pharm. Bull.*, **41**, 1733 (1993); Noda N., Tanaka R., Miyahara K., *ibid.*, **42**, 1247 (1994); Noda N., Tanaka R., Tsujino K., Takasaki Y., Nakano M., Nishi M., Miyahara K., *J. Biochem. (Tokyo)*, **116**, 435 (1994).
- Noda N., Tanaka R., Nishi M., Shoji I., Miyahara K., *Chem. Pharm. Bull.*, **41**, 1366 (1993); Tanaka R., Hashimoto A., Noda N., Miyahara K., *ibid.*, **43**, 156 (1995).
- Noda N., Tanaka R., Tsujino K., Miura M., Miyahara K., Hayakawa J., *Chem. Pharm. Bull.*, **43**, 567 (1995).
- Hara S., Okabe H., Mihashi K., *Chem. Pharm. Bull.*, **35**, 501 (1987).
- Vincenti M., Guglielmetti G., Cassani G., Tonini C., *Anal. Chem.*, **59**, 694 (1987).
- Fusetani N., Yasumoto K., Matsunaga S., *Tetrahedron Lett.*, **30**, 6891 (1987).
- Gunstone F. D., Pollard M. R., Scrimgeour C. M., Vedanayagam H. S., *Chem. Phys. Lipids*, **18**, 115 (1977).
- Kohata K., Ohtaki E., Suzuki C., Meguro H., *Nippon Kagaku Kaishi*, **1982**, 1609.
- Sugita and co-workers have recently examined the GSLs in the same materials, and have reported the presence of ceramide galactosides having Galβ1–Cer, Galα1–6Galβ1–Cer or Galα1–6Galα1–6Galβ1–Cer saccharide linkages as a mixture of analogs. Sugita M., Morikawa A., Nakaya F., Hori T., Abstracts of Papers Presented at the 67th Annual Meeting of the Japanese Biochemical Society, Osaka, September 1994, p. 971.